Compare AME & IQV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AME | IQV |
|---|---|---|
| Founded | 1930 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.1B | 36.4B |
| IPO Year | N/A | 2013 |
| Metric | AME | IQV |
|---|---|---|
| Price | $201.62 | $225.19 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 17 |
| Target Price | $215.50 | ★ $237.59 |
| AVG Volume (30 Days) | ★ 1.4M | 1.4M |
| Earning Date | 10-30-2025 | 10-28-2025 |
| Dividend Yield | ★ 0.61% | N/A |
| EPS Growth | ★ 10.46 | N/A |
| EPS | 6.34 | ★ 7.30 |
| Revenue | $7,164,270,000.00 | ★ $15,904,000,000.00 |
| Revenue This Year | $6.80 | $6.14 |
| Revenue Next Year | $7.61 | $5.35 |
| P/E Ratio | $32.15 | ★ $30.94 |
| Revenue Growth | 3.67 | ★ 3.85 |
| 52 Week Low | $145.02 | $134.65 |
| 52 Week High | $204.24 | $234.30 |
| Indicator | AME | IQV |
|---|---|---|
| Relative Strength Index (RSI) | 58.25 | 54.25 |
| Support Level | $195.82 | $217.86 |
| Resistance Level | $201.39 | $230.80 |
| Average True Range (ATR) | 3.16 | 5.09 |
| MACD | 0.32 | -0.94 |
| Stochastic Oscillator | 66.35 | 51.27 |
Founded in 1930 and transformed over the decades through the acquisition of dozens of esteemed brands, Ametek owns a collection of over 40 autonomous industrial businesses operating within the research, aerospace, energy, medical, and manufacturing industries. Ametek segments its business into two operating groups: the electronic instruments group and the electromechanical group. The EIG sells a broad portfolio of analytical, test, and measurement instruments, while the EMG sells highly engineered components, interconnects, and specialty metals. The company emphasizes product differentiation and market leadership in the niche markets where it operates.
Iqvia is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.